As Eupraxia Pharmaceuticals prepares to release its earnings report, investors are closely watching for signs of improvement in its financial performance.
Eupraxia Pharmaceuticals Inc (EPRX.TO) is set to announce its earnings on August 11, 2026, after the market closes. With a consensus EPS estimate of -$0.24, the company faces pressure to reverse a trend of disappointing earnings reports. Over the last four quarters, Eupraxia has not met analyst expectations, raising questions about its ability to turn things around in this upcoming report.
Recent earnings trend
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$617.99M
52W high
$12.86
52W low
$6.94
1W change
+5.35%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 69.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.00
+69.1% Upside
Current Price
C$9.46
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
57.0%
Annualized
90-Day Vol
56.2%
Annualized
Trend (90d)
-44.2%
Annualized drift
90d Mean
C$8.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.98 | C$7.37 – C$10.92 |
| 60 trading days | C$8.51 | C$6.45 – C$11.24 |
| 90 trading days | C$8.08 | C$5.75 – C$11.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 4 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-11 | — | -0.2400 | — |
| 2026-03-31 | 2026-05-07 | -0.3201 | -0.1900 | -68.5% |
| 2025-12-31 | 2026-03-12 | -0.5000 | -0.2200 | -127.3% |
| 2025-09-30 | 2025-11-04 | -0.2700 | -0.2700 | +0.0% |
| 2025-06-30 | 2025-08-12 | -0.3600 | -0.2500 | -44.0% |
| 2025-03-31 | 2025-05-06 | -0.2900 | -0.2300 | -26.1% |
Advertisement
Investor takeaway: Keep an eye on Eupraxia's earnings report. With a history of missing expectations and a downward revision in EPS estimates, the upcoming results could be crucial for the company's stock trajectory.
Upcoming EPS Estimate: -$0.24
Eupraxia has not beaten EPS estimates in its last four quarters, with a historical average EPS of -$0.36, indicating a challenging path ahead.
Bull case
If Eupraxia can exceed the -$0.24 EPS estimate, it might signal a turnaround in its financial performance and boost its stock, potentially attracting more investor interest.
Bear case
On the other hand, failing to meet expectations again could further erode investor confidence, especially given the recent trend of negative surprises and the downward revision of EPS estimates.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
